U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
CAMBRIDGE, Mass., May 10, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
Bank of America Merrill Lynch 2017 Health Care Conference
Wednesday, May 17, 2017 at 12:20 p.m. ET in Las Vegas, NV
UBS Global Healthcare Conference
Tuesday, May 23, 2017 at 9:00 a.m. ET in New York, NY
A webcast of each presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of each presentation will be posted on the Momenta website approximately one hour after each event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
